For Doctors in a Hurry
- Guidelines recommend neuromuscular blockade for refractory elevated intracranial pressure, but its real-world physiologic effect remains poorly quantified.
- Researchers conducted a retrospective before-after study of 106 intensive care patients receiving continuous rocuronium infusions and invasive intracranial pressure monitoring.
- Median intracranial pressure decreased from 20.7 to 18.6 millimeters of mercury, while cerebral perfusion pressure increased from 71.1 to 75.2 (P<0.001).
- The authors concluded that continuous rocuronium infusion provides modest reductions in intracranial pressure of approximately one to two millimeters of mercury.
- Although these physiologic changes are small and may have limited clinical significance, the findings directly inform current neurocritical care guidelines.
The Clinical Reality of Paralyzing for Brain Pressure
Managing severe traumatic brain injury and neurocritical illness requires aggressive intervention to prevent secondary neurological damage [1]. In the intensive care unit, clinicians routinely rely on a complex array of sedatives and anesthetics to maintain strict hemodynamic stability and control intracranial pressure [2, 3]. While continuous neuromuscular blockade (the administration of paralytic medications to halt skeletal muscle movement) is a well-established tool for managing severe respiratory failure [4], neurocritical care guidelines also recommend it as a secondary option for refractory intracranial hypertension, or dangerously high pressure within the skull. Despite this physiological rationale, the actual impact of systemic paralysis on brain pressure has remained poorly quantified in everyday clinical practice. A retrospective analysis of 106 patients receiving continuous rocuronium infusions now clarifies this effect, demonstrating that median intracranial pressure decreased from 20.7 to 18.6 mm Hg (a within-patient change of -0.9 mm Hg; p=0.017) and cerebral perfusion pressure (the net pressure gradient driving blood flow to the brain) increased from 71.1 ± 10.5 to 75.2 ± 12.5 mm Hg (p<0.001) [5].
Quantifying a Guideline Recommendation
Contemporary intracranial hypertension guidelines, including the 2019 Seattle International Severe Traumatic Brain Injury Consensus Conference and the 2024 American College of Surgeons Best Practices, list neuromuscular blockade as a Tier Two, short-duration option for refractory intracranial pressure elevation. Despite this formal recommendation, the actual clinical benefit has remained largely theoretical. Prior to this study, the real-world effect of initiating continuous paralysis on intracranial pressure had not been quantified using large-scale intra-patient physiologic data. To address this evidence gap, the researchers performed a retrospective intra-patient before-after study at a Level 1 trauma and neurocritical care center from 2016 to 2021. Out of 9,373 intensive care unit admissions, the investigators identified 106 patients who received a rocuronium infusion with continuous invasive intracranial pressure monitoring. The researchers compared intracranial pressure values using symmetric pre-treatment and post-treatment windows of -165 to 0 minutes and +15 to 180 minutes. Because neurocritical care patients receive multiple overlapping treatments, the team utilized a generalized additive model (a statistical technique that captures complex, non-linear relationships over time) to evaluate time-dependent pressure changes. Importantly, this model adjusted for concurrent sedatives and hypertonic saline, isolating the specific physiological impact of the continuous rocuronium infusion from other medical interventions.
Tracking Time-Dependent Pressure Changes
When evaluating the subset of patients experiencing more severe intracranial hypertension, the researchers identified a slightly more pronounced physiological response. Specifically, in patients with a pre-treatment intracranial pressure greater than 20 mm Hg, the median change in intracranial pressure was -2.0 mm Hg (p < 0.001). While this reduction is statistically significant, clinicians must weigh whether a two-point drop provides meaningful therapeutic benefit for a patient in acute neurological distress. To understand how this intervention performs over a longer duration, the investigators utilized their adjusted statistical model to track pressure trajectories. This modeling demonstrated an intracranial pressure reduction of -1.66 mm Hg at 3 hours. As the continuous rocuronium infusion progressed, the reduction reached -2.23 mm Hg at 6 hours. These time-dependent metrics confirm that while continuous neuromuscular blockade does reliably lower intracranial pressure, the absolute magnitude of the reduction remains modest even several hours after initiation.
Weighing the Clinical Significance
For practicing neurointensivists, these data provide a sobering perspective on a common intervention. The researchers concluded that continuous rocuronium infusion was associated with modest reductions in intracranial pressure of approximately 1 to 2 mm Hg, alongside improved cerebral perfusion pressure. However, the authors explicitly note that these physiologic changes are small and may have limited clinical significance. When managing a patient with severe traumatic brain injury or refractory intracranial hypertension, a reduction of only 1 to 2 mm Hg might not alter the overall clinical trajectory or avert the need for surgical decompression. Clinicians must weigh this marginal benefit against the known risks of prolonged neuromuscular blockade, such as critical illness myopathy and the masking of underlying seizure activity. Despite the modest effect size, the structural value of this research is substantial. The authors emphasize that this study provides the largest real-world evaluation and quantification of the effect of continuous neuromuscular blockade on intracranial pressure control. By analyzing high-resolution, intra-patient physiologic data rather than relying on theoretical mechanisms, the findings directly inform a major evidence gap highlighted in contemporary guidelines. Physicians now have concrete data to guide their expectations, confirming that while paralyzing agents do reliably lower brain pressure, they should be viewed as a minor adjunct rather than a definitive solution for severe intracranial hypertension.
References
1. Tobin JM, Grabinsky A, McCunn M, et al. A Checklist for Trauma and Emergency Anesthesia. Anesthesia & Analgesia. 2013. doi:10.1213/ane.0b013e3182a44d3e
2. Ko E, Je LG, Kim JH, Song YJ, Lim CH. Effects of Remimazolam versus Sevoflurane on Hemodynamics in Patients Undergoing Coil Embolization of Cerebral Aneurysm: A Prospective Randomized Controlled Trial. Journal of Clinical Medicine. 2024. doi:10.3390/jcm13133958
3. Lee HH, Kim H, Lee JE, et al. The Effect of a Transdermal Scopolamine Patch on Postoperative Nausea and Vomiting after Retromastoid Craniectomy with Microvascular Decompression: A Preliminary Single Center, Double-Blind, Randomized Controlled Trial. Journal of Clinical Medicine. 2020. doi:10.3390/jcm9010156
4. Papazian L, Forel J, Gacouin A, et al. Neuromuscular Blockers in Early Acute Respiratory Distress Syndrome. New England Journal of Medicine. 2010. doi:10.1056/nejmoa1005372
5. Goder N, Rubenfeld GD, Amaral ACKB. Neuromuscular Blockade for Intracranial Hypertension: Quantifying Real-World Effectiveness on Intracranial Pressure.. Journal of intensive care medicine. 2026. doi:10.1177/08850666261432119
